CBT Program Shows Promise for African Americans With Mild Cognitive Impairment
A pilot trial tests whether group and phone-based CBT can sharpen cognition and cut chronic stress in African Americans at risk for Alzheimer's.
Summary
Researchers at Emory University ran a small randomized trial to test whether a six-month cognitive-behavioral therapy program could improve brain function and lower chronic stress in African American adults with Mild Cognitive Impairment, a condition that significantly raises Alzheimer's risk. Thirty-one participants were assigned to either group-based CBT, phone-based CBT, or usual care. The study focused first on feasibility and acceptability, meaning whether patients actually enrolled, stayed engaged, and found the program useful, before examining cognitive and stress outcomes. African Americans are disproportionately affected by Alzheimer's disease yet remain underrepresented in prevention trials, making this culturally targeted approach particularly meaningful. Results from this completed pilot will help determine the right intensity and delivery format for larger future trials aimed at closing a critical health equity gap.
Detailed Summary
Alzheimer's disease affects African Americans at roughly twice the rate of non-Hispanic white Americans, yet this population remains dramatically underrepresented in prevention and treatment research. Addressing that gap requires both culturally relevant interventions and feasibility data to support larger trials. This pilot study from Emory University was designed to do exactly that.
Researchers enrolled 31 African American adults diagnosed with Mild Cognitive Impairment, a transitional stage between normal aging and dementia that carries significant Alzheimer's risk. Participants were randomized to one of three arms: group-based CBT sessions, phone-based CBT sessions, or usual care as a control. The six-month program targeted both cognitive performance and chronic stress reduction, given that chronic psychological stress is increasingly recognized as a modifiable risk factor for cognitive decline.
The primary objectives were feasibility and acceptability — determining whether this population would enroll, adhere, and find the intervention useful. Secondary goals included preliminary signals on cognitive outcomes and stress biomarkers. The phone-based arm was included to test whether remote delivery could widen access for participants facing transportation or scheduling barriers, a practical consideration in underserved communities.
The trial was completed in November 2019. While full efficacy results are not available from the abstract alone, the study was designed to generate effect size estimates and optimal dosing data to power a larger definitive trial. If CBT proves effective, it offers a low-cost, scalable, non-pharmacological tool that could be deployed in community health settings.
Caveats are significant. The sample of 31 is too small to draw firm efficacy conclusions, and results may not generalize beyond the specific study population. Nonetheless, this trial fills an important methodological and ethical gap in Alzheimer's prevention research by centering a high-risk, underserved group.
Key Findings
- CBT delivered in-group or by phone was tested as a non-drug strategy to slow cognitive decline in African Americans with MCI.
- Chronic stress was a primary target, reflecting growing evidence that psychological stress accelerates Alzheimer's risk.
- Phone-based delivery was included to improve access in communities with transportation or scheduling barriers.
- The trial prioritized health equity by focusing exclusively on a population disproportionately burdened by Alzheimer's disease.
- Feasibility data from this pilot will inform the design of larger, adequately powered prevention trials.
Methodology
This was a small randomized controlled pilot trial (n=31) with three arms: group CBT, phone CBT, and usual care, conducted over six months at Emory University. The study was explicitly designed to assess feasibility and acceptability as primary endpoints, with cognitive performance and stress reduction as secondary outcomes. Phase was listed as NA, consistent with a feasibility rather than efficacy-focused design.
Study Limitations
The sample size of 31 is too small to support efficacy conclusions, and results should be interpreted as preliminary signals only. The summary is based on the abstract only; full outcome data, retention rates, and stress biomarker results are not available. Findings may not generalize to African American populations in different geographic or socioeconomic contexts.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.